Two Different Approaches During Fluoroscopically Guided Interlaminar Lumbar Epidural Steroid Injection
This study is ongoing, but not recruiting participants.
Sponsor:
Kenneth D Candido
Information provided by (Responsible Party):
Kenneth D Candido, Chicago Anesthesia Pain Specialists
ClinicalTrials.gov Identifier:
NCT01760317
First received: December 21, 2012
Last updated: January 3, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare two different approaches (midline and parasagittal) during interlaminar lumbar epidural steroid injection (LESI), and to verify the role of concordant pressure paresthesia occurring during the LESI in determining outcome.
The investigators are planning to include 100 patients, undergoing LESI for radicular low back pain. This will be single-blinded randomized study. Every patient will receive the same medication we would use regardless of participating in the study. The patients will be randomly assigned to one of two groups, based on the approach:
- Group I (50 patients) - will get LESI using midline (MIL) approach.
- Group II (50 patients) - will get LESI using parasagittal interlaminar (PIL) approach.
| Condition | Intervention |
|---|---|
|
Unilateral Lumbosacral Radiculopathy Pain |
Procedure: Midline vs Parasagittal Lumbar Epidural Steroid Injection |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Midline vs Lateral Parasagittal Approach During Fluoroscopically Guided Interlaminar Lumbar Epidural Steroid Injection: the Role of Concordant Pressure Paresthesia in Determing Outcome. |
Further study details as provided by Chicago Anesthesia Pain Specialists:
Primary Outcome Measures:
- Changes in Pain Scores from baseline after Lumbar Epidural Steroid Injection [ Time Frame: Days 1, 7, 14, 21, 28, 60, 120, 180, 360 ] [ Designated as safety issue: No ]
- Pressure Paresthesia during injection [ Time Frame: 1 day (During Lumbar Epidural Steroid Injection) ] [ Designated as safety issue: No ]
- Quality of life improvement change after Lumbar Epidural Steroid Injection [ Time Frame: Days 1, 7, 14, 21, 28, 60, 120, 180, 360 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | August 2010 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Midline
Midline Lumbar Epidural Steroid Injection
|
Procedure: Midline vs Parasagittal Lumbar Epidural Steroid Injection |
|
Active Comparator: Parasagittal
Parasagittal Lumbar Epidural Steroid Injection
|
Procedure: Midline vs Parasagittal Lumbar Epidural Steroid Injection |
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 18- 80 years old
- History of low back pain and unilateral lumbosacral radiculopathy pain
- Lumbar disk disease including disk herniations, bulging discs, and degenerated discs, where at least 50% of the disk height is preserved respective to contiguous levels
Exclusion Criteria:
- Discogenic pain without radiculopathy pain
- History of previous spinal surgery
- LESI(s) in the past year
- Allergy to methylprednisolone, or lidocaine, or iodine-based contrast
- Concurrent use of systemic steroid medications
- Opioid habituation
- Pregnancy
Contacts and Locations
More Information
Publications:
| Responsible Party: | Kenneth D Candido, Chairman of Anesthesia Department; Advocate Illinois Masonic Medical Center, Chicago Anesthesia Pain Specialists |
| ClinicalTrials.gov Identifier: | NCT01760317 History of Changes |
| Other Study ID Numbers: | Advocate-IRB-4917 |
| Study First Received: | December 21, 2012 |
| Last Updated: | January 3, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Radiculopathy Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013